Publication
Navigating the IPO
Taking your company public is an important milestone, and whilst the landscape for IPOs is complex and dynamic, choosing the right path is essential.
Global | Publication | February 2016
Case: The Dow Chemical Company v Nova Chemical Corporation, 2016 FC 91
Nature of case: Costs decision
Successful party: Dow Chemical Company, Dow Global Technologies Inc. and Dow Chemical Canada ULC
Date of decision: January 22, 2016
Justice O’Keefe of the Federal Court awarded the plaintiffs of a successful patent infringement proceeding, Dow Chemical Company, Dow Global Technologies Inc. and Dow Chemical Canada ULC (Dow), a lump sum payment of $2.9 million for legal fees and $3.6 million for reasonable and necessary disbursements.
At the liability stage of the action, Dow was granted a declaration that the defendant, Nova Chemical Corporation (Nova) had infringed Canadian Patent No. 2,160,705, and was awarded costs of the proceeding (Dow Chemical Company v Nova Chemicals Corporation, 2014 FC 844).
The trial was complex, extended over 32 days and involved expert testimony. In addition, both parties carried out large amounts of testing.
Nova argued that Dow’s costs should be prescribed by the tariff rates under the Federal Court Rules, which would have restricted the costs award to $1,099,725, or only 11% of Dow’s legal costs. Justice O’Keefe stated that this would be “totally inadequate” and “[t]o only recoup 11% of your costs in such a complex case is not acceptable.”
Justice O’Keefe found that a lump sum award of 30% of Dow’s legal fees was more appropriate. He considered the following factors, among others, in awarding the increased costs award:
Justice O’Keefe also awarded $3.6 million for reasonable and necessary disbursements.
The Dow Chemical Company v Nova Chemical Corporation, 2016 FC 91
Publication
Taking your company public is an important milestone, and whilst the landscape for IPOs is complex and dynamic, choosing the right path is essential.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright US LLP 2025